FDA expands VOXZOGO approval for all ages with open growth plates
BioMarin Pharmaceutical Inc., a leading global biotechnology entity, unveiled that its drug, VOXZOGO (vosoritide), has received the green light from the U.S. Food and Drug ... Read More
BioMarin, DiNAQOR to develop gene therapies for rare genetic cardiomyopathies
BioMarin Pharmaceutical has signed a preclinical collaboration and license deal with Swiss gene therapy platform company DiNAQOR to develop novel gene therapies for the treatment ... Read More